Nalge Nunc to Market High-Content Screening Tool
By Biotechdaily staff writers
Posted on 02 Jun 2006
Nalge Nunc International Corporation (Rochester, NY, USA) has announced an agreement with Molecular Cytomics Inc. (Boston, MA, USA), a biotechnology company that develops high content, cell-based technologies. The agreement provides global distribution rights to Nalge Nunc International for the sale and support of Molecular Cytomics' first product family, the Optical LiveCell array.Posted on 02 Jun 2006
The products will be marketed under the brand name Nunc LiveCell array, and will consist of specialized microscope slides and kits with reagents for apoptosis and cell surface marker assays. The slide-based high content analysis (HCA) and screening tool enables real-time, non-intrusive analysis of adhering or non-adhering living cells within heterogeneous populations. Scientists will be able to study individual cells in micron-sized wells with an assigned location using a standard laboratory microscope.
The disposable, sterile microscope slides have an embedded transparent array of picowells. This enables multiple functional assays on living cells followed by post-fixation studies on the same cells. The processes of staining, rinsing, and perfusions do not displace the cells. Image analysis software designates an address to each cell. Product support will be supplied by the research laboratory staff at Nalge Nunc International.
Nalge Nunc International manufactures, designs, and develops products for use in labware, packaging, biotech, environmental, and life science applications.
Related Links:
Nalge Nunc International
Molecular Cytomics